We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abeona Restarts Enrollment in Connective Tissue Disorder Study
Read MoreHide Full Article
Abeona Therapeutics Inc. announced that it has restarted patient enrollment in the pivotal phase III VIITAL study of EB-101. EB-101 is an autologous, gene-corrected cell therapy being evaluated for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy.
Enrollment in the VIITAL study was paused in March 2020 in order to redirect healthcare resources to COVID-19 patients and ensure the safety of study participants and site staff.
Shares of the company have gained 4.5% year to date compared with the industry’s growth of 12.8%.
The VIITAL study is enrolling 10 to 15 RDEB patients with about 30 large, chronic wound sites treated in total.Treatment with EB-101 involves using gene transfer to deliver COL7A1 genes into a patient’s skin cells (keratinocytes and its progenitors) and transplanting them back to the patient to enable normal Type VII collagen expression and facilitate wound healing.
The company also announced that two ongoing studies of its investigational adeno-associated virus (AAV)-based gene therapies, ABO-102 and ABO-101 have continued to treat patients, with additional enrollment expected in the programs in the coming weeks. The phase I/II Transpher A study (NCT02716246) is evaluating ABO-102 for the treatment of patients with Sanfilippo syndrome type A mucopolysaccharidosis type IIIA (MPS IIIA). The study, also known as ABT-001, is intended for patients aged 6 months to 2 years, or those older than 2 years with a cognitive Developmental Quotient of 60% or above.
The phase I/II Transpher B Study (NCT03315182) is assessing ABO-101 for the treatment of patients with Sanfilippo syndrome type B (MPS IIIB). The study, also known as ABT-002, is intended for patients from birth to 2 years of age, or those older than 2 years with a cognitive Developmental Quotient of 60% or above.
Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.
Bristol Myers’ earnings per share estimates have increased from $6.12 to $6.16 for 2020 and from $7.31 to $7.37 for 2021 in the past 60 days.
BioMarin’s earnings per share estimates have increased from $1.51 to $1.56 for 2020 and from $2.46 to $2.79 for 2021 in the past 60 days.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020? Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Abeona Restarts Enrollment in Connective Tissue Disorder Study
Abeona Therapeutics Inc. announced that it has restarted patient enrollment in the pivotal phase III VIITAL study of EB-101. EB-101 is an autologous, gene-corrected cell therapy being evaluated for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy.
Enrollment in the VIITAL study was paused in March 2020 in order to redirect healthcare resources to COVID-19 patients and ensure the safety of study participants and site staff.
Shares of the company have gained 4.5% year to date compared with the industry’s growth of 12.8%.
The VIITAL study is enrolling 10 to 15 RDEB patients with about 30 large, chronic wound sites treated in total.Treatment with EB-101 involves using gene transfer to deliver COL7A1 genes into a patient’s skin cells (keratinocytes and its progenitors) and transplanting them back to the patient to enable normal Type VII collagen expression and facilitate wound healing.
The company also announced that two ongoing studies of its investigational adeno-associated virus (AAV)-based gene therapies, ABO-102 and ABO-101 have continued to treat patients, with additional enrollment expected in the programs in the coming weeks. The phase I/II Transpher A study (NCT02716246) is evaluating ABO-102 for the treatment of patients with Sanfilippo syndrome type A mucopolysaccharidosis type IIIA (MPS IIIA). The study, also known as ABT-001, is intended for patients aged 6 months to 2 years, or those older than 2 years with a cognitive Developmental Quotient of 60% or above.
The phase I/II Transpher B Study (NCT03315182) is assessing ABO-101 for the treatment of patients with Sanfilippo syndrome type B (MPS IIIB). The study, also known as ABT-002, is intended for patients from birth to 2 years of age, or those older than 2 years with a cognitive Developmental Quotient of 60% or above.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. price | Abeona Therapeutics Inc. Quote
Zacks Rank and Stocks to Consider
Abeona is currently a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Emergent Biosolutions Inc. (EBS - Free Report) , Bristol Myers Squibb Company (BMY - Free Report) and BioMarin Pharmaceuttical Inc. (BMRN - Free Report) , all carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.
Bristol Myers’ earnings per share estimates have increased from $6.12 to $6.16 for 2020 and from $7.31 to $7.37 for 2021 in the past 60 days.
BioMarin’s earnings per share estimates have increased from $1.51 to $1.56 for 2020 and from $2.46 to $2.79 for 2021 in the past 60 days.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020? Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>